Enlivex Debt To Assets from 2010 to 2025

ENLV Stock  USD 1.10  0.01  0.90%   
Enlivex Therapeutics Debt To Assets yearly trend continues to be fairly stable with very little volatility. Debt To Assets will likely drop to 0.02 in 2025. During the period from 2010 to 2025, Enlivex Therapeutics Debt To Assets regression line of quarterly data had mean square error of  0.0002 and geometric mean of  0.01. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.0252
Current Value
0.0189
Quarterly Volatility
0.01692432
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 15.3 K, Total Revenue of 0.0 or Research Development of 23.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.82. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Latest Enlivex Therapeutics' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Enlivex Therapeutics over the last few years. It is Enlivex Therapeutics' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enlivex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Enlivex Debt To Assets Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation120.17
Mean Deviation0.01
Median0.01
Standard Deviation0.02
Sample Variance0.0003
Range0.0666
R-Value0.50
Mean Square Error0.0002
R-Squared0.25
Significance0.05
Slope0
Total Sum of Squares0

Enlivex Debt To Assets History

2025 0.0189
2024 0.0252
2023 0.028
2022 0.0717
2021 0.006485
2020 0.00503

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' Debt To Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.03  0.02 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.